Vertex (NASDAQ: VRTX) Thursday announced data from a Phase 3 study of ivacaftor in 69 people 6 years of age ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE